Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Daklinza Daclatasvir Hepatitis C, Chronic List with clinical criteria and/or conditions Complete
Daklinza daclatasvir Hepatitis C, Chronic Reimburse with clinical criteria and/or conditions Complete
Cystadrops cysteamine Corneal cystine crystal deposits Reimburse with clinical criteria and/or conditions Complete
Cyramza Ramucirumab Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma Reimburse with clinical criteria and/or conditions Complete
Cyramza Ramucirumab Cancelled
Cymbalta Duloxetine hydrochloride Pain, Neuropathic, Diabetic List with clinical criteria and/or conditions Complete
Cymbalta Duloxetine hydrochloride Depressive, Major Disorder (MDD) Do not list Complete
Cuvposa glycopyrrolate chronic severe drooling, neurologic (pediatric) Do not reimburse Complete
Cubicin Daptomycin Skin and skin structure infections & bacteremia Do not list Complete
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active